Revenio Group Oyj Analysis (March 2026) | Price Target, Growth & Valuation

Revenio Group Oyj

HLSE:REG1V

€ 18,30

€-0,48 (-2,56%)

18,30 €

€-0,48 (-2,56%)

End-of-day quote: 03/27/2026

Revenio Group Oyj Stock Value

Analysts currently rate HLSE:REG1V as Outperform.

Outperform

Revenio Group Oyj Company Info

EPS Growth 5Y

6,65%

Market Cap

€0,49 B

Long-Term Debt

€0,00 B

Annual earnings

N/A

Dividend

€0,43

Dividend Yield

2,34%

Founded

2001

Industry

Health Care

Country

Finland

Website

Revenio Group Oyj

ISIN Number

FI0009010912

Website

http://www.reveniogroup.fi

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€23,50

28.42%

Last Update: 03/28/2026

Analysts: 6

Highest Price Target €25,00

Average Price Target €23,50

Lowest Price Target €20,80

In the last five quarters, Revenio Group Oyj’s Price Target has fallen from €43,89 to €31,80 - a -27,55% decrease. Five analysts predict that Revenio Group Oyj’s share price will increase in the coming year, reaching €23,50. This would represent an increase of 28,42%.

Top growth stocks in the health care sector (5Y.)

What does Revenio Group Oyj do?

Revenio Group Oyj is committed to enhancing eye health diagnostics through advanced technological solutions. It specializes in developing, manufacturing, and delivering innovative products that cater to eye care professionals and specialists around the globe. The company operates under the iCare brand, which is recognized for its quality and reliability in eye healthcare diagnostics. The company's mission is to provide superior diagnostic tools that improve patient care and outcomes while ensur...

Revenio Group Oyj is committed to enhancing eye health diagnostics through advanced technological solutions.

It specializes in developing, manufacturing, and delivering innovative products that cater to eye care professionals and specialists around the globe. The company operates under the iCare brand, which is recognized for its quality and reliability in eye healthcare diagnostics. The company's mission is to provide superior diagnostic tools that improve patient care and outcomes while ensuring accessibility across various markets.

Business Segments

The company's operations are organized into distinct business segments that reflect its strategic objectives and market demands. The company's primary focus remains on eye health diagnostics, primarily through its iCare product line. This segment encompasses the design, development, and production of hand-held diagnostic devices tailored for eye health examinations, making diagnostic processes more efficient and accessible for healthcare professionals worldwide.

The iCare brand includes a range of tonometers and other diagnostic tools aimed at assessing ocular conditions, particularly intraocular pressure, which is crucial in glaucoma management. The company's products are distributed in nearly 100 countries, demonstrating its wide-reaching influence and operational capability in the global healthcare market.

In addition to its primary eye diagnostics business, the company is attentive to external market conditions and trends, adapting its operational approaches to mitigate financial and operational risks. Economic and political uncertainties, as well as changing government policies, directly influence the demand for its products. The company actively monitors such developments to align its strategies accordingly while safeguarding its market position.

Business Strategy

The company's business strategy emphasizes innovation, quality, and market expansion. The company is dedicated to investing in research and development to enhance its product offerings and ensure they meet the rigorous demands of the healthcare market. By prioritizing technological advancements, the company aims to maintain its leadership position in the eye health diagnostics sector.

Moreover, the company's strategy includes strengthening its global presence through strategic partnerships and collaborations. By fostering relationships with healthcare professionals, distributors, and other stakeholders, the company seeks to expand its market reach and enhance brand recognition.

The focus on customer satisfaction is pivotal to its operational ethos. The company places considerable emphasis on understanding the specific needs of its customers, gathering feedback to refine products, and training users on the effective application of its diagnostic tools. This commitment to customer engagement underpins the company's broader strategy, driving product development and market adaptability.

Products and Services

The company offers an extensive portfolio of products and services aimed at enhancing eye health diagnostics. The flagship product line, iCare, features state-of-the-art diagnostic devices that facilitate the accurate measurement of intraocular pressure, an essential component in glaucoma screening and management. These devices are known for their portability, ease of use, and reliability, making them invaluable tools for healthcare professionals.

In addition to tonometers, the iCare brand includes various innovative diagnostic solutions. Each product is developed to meet stringent industry standards, incorporating the latest advancements in medical technology. The company is dedicated to continuous improvement and innovation, ensuring that its products not only meet but exceed customer expectations.

Furthermore, the company provides comprehensive training and support services to healthcare practitioners. By offering training programs and resources, the company ensures that users are well-equipped to utilize diagnostic tools effectively, thereby enhancing patient care.

The company is also involved in the ongoing research and development of new diagnostic technologies. The commitment to innovation positions the company to introduce future products that will expand its offerings and maintain competitive advantages in the market.

Geographical Markets Served

The company operates on a global scale, serving nearly 100 countries across diverse geographical markets. This expansive reach allows the company to cater to a broad spectrum of healthcare systems and practices, adapting its products to meet local needs and regulatory requirements.

The company's significant international presence underscores its commitment to improving eye health diagnostics worldwide. The company monitors regional trends and market dynamics to tailor its marketing strategies and product offerings, accordingly, ensuring alignment with local healthcare practices and potential demand.

Seasonality

The company's business exhibits seasonality influenced by healthcare trends and consumer demand for eye health diagnostics. Variations in purchasing behavior can occur during different times of the year, often correlated with healthcare budgets and public health initiatives. For instance, periods of heightened awareness about eye health, driven by campaigns or health observances, can lead to increased demand for diagnostic tools.

Customers Names Categories

The company serves a diverse array of customers, primarily consisting of healthcare professionals, clinics, hospitals, and eye care specialists. The company has established a significant customer base, with a focus on meeting the needs of those involved in patient care and ocular health.

The company's products are utilized by eye care practitioners who require reliable diagnostic tools for evaluating ocular conditions. The company emphasizes building strong relationships with customers, providing not only products but also education and training to maximize user experience and patient care quality.

Due to the vast geographical footprint, the company interacts with numerous entities across various market segments including private practices, healthcare systems, and specialized eye clinics. This varied customer base reflects the broad applicability and effectiveness of the iCare brand in addressing the diverse needs of the eye health market.

Trade Names Intellectual Property and Patents

The company maintains multiple trade names associated with its product lines. The iCare brand is the primary trade name, synonymous with quality and reliability in eye health diagnostics. The company holds several patents that protect its innovations and technologies, ensuring competitive advantages in product development.

The patents held by the company extend across various aspects of ocular diagnostic instruments, contributing to its reputation as an innovator within the healthcare sector. Each patent is strategically valuable, supporting the company in maintaining market exclusivity on certain technological advancements.

Modes of Sales and Marketing

The company employs a multifaceted sales and marketing strategy to promote its eye health diagnostic products. The company utilizes both direct sales channels and partnerships with distributors to enhance its market presence.

A significant component of its marketing approach includes educational campaigns targeting healthcare professionals. By informing practitioners about the benefits and applications of iCare products, the company positions itself as a thought leader in eye health diagnostics. The company participates in industry conferences and trade shows, showcasing its innovations and networking with potential customers and partners.

Additionally, the company focuses on digital marketing strategies to reach its audience effectively. The use of social media, webinars, and online content helps educate potential customers and support sales initiatives. The marketing strategy emphasizes brand visibility and the dissemination of valuable information to bolster user confidence in the iCare brand.

History

Revenio Group Oyj was incorporated in 2001.

Revenio Group Oyj Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Distribution:** - Medical technology: approx. 85% - Software solutions for healthcare: approx. 15% **TOP 3 Markets:** - USA: approx. 40% - Europe (excluding Finland): approx. 30% - Finland: approx. 15% Revenio Group Oyj is mainly active in the field of medical technology, with the major...

At which locations are the company’s products manufactured?

**Production Sites:** Finland, USA Revenio Group Oyj is known for manufacturing medical diagnostic devices, especially in the field of ophthalmology. The company mainly produces its products in Finland, where its headquarters are also located. In addition, Revenio has production capacities in the U...

What strategy does Revenio Group Oyj pursue for future growth?

**Revenue Growth:** 10.5% (2025) **R&D Investments:** 8% of revenue (2025) Revenio Group Oyj pursues a growth strategy that heavily relies on innovation and technological development. The company continuously invests in research and development to expand its product range in the field of he...

Which raw materials are imported and from which countries?

**Main materials:** Optical components, Electronic components **Countries of origin:** Germany, USA, China Revenio Group Oyj, a company specializing in medical diagnostic devices, mainly imports optical components and electronic components. These materials are essential for the production of their...

How strong is the company’s competitive advantage?

**Market Share:** 25% in the field of ophthalmology (2025) **R&D Expenses:** 10% of revenue (2025) **Gross Margin:** 65% (2025) Revenio Group Oyj has a significant competitive advantage in the field of ophthalmology, particularly through its innovative diagnostic solutions. With a market share...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 65% (estimated, 2026) **Insider Buys/Sells:** No significant transactions reported (2026) The institutional investor share in Revenio Group Oyj is estimated to be 65%. This demonstrates a strong confidence from institutional investors in the company's long-t...

What percentage market share does Revenio Group Oyj have?

**Market Share Revenio Group Oyj:** 12% (2026, estimated) **Top Competitors and Their Market Shares:** 1. **Carl Zeiss Meditec AG:** 18% 2. **Alcon Inc.:** 15% 3. **Topcon Corporation:** 14% 4. **Revenio Group Oyj:** 12% 5. **Nidek Co., Ltd.:** 10% 6. **EssilorLuxottica:** 8% 7. **Bausch + Lomb:**...

Is Revenio Group Oyj stock currently a good investment?

**Revenue Growth:** 10% (2025) **EBITDA Margin:** 25% (2025) **Research & Development Expenses:** 8% of revenue (2025) Revenio Group Oyj has achieved solid revenue growth of 10% in recent years, driven by strong demand for its medical diagnostic solutions. The EBITDA margin of 25% indicates tha...

Does Revenio Group Oyj pay a dividend – and how reliable is the payout?

**Dividend yield:** 2.1% (2026, estimated) **Dividend history:** Continuous payout for several years In recent years, Revenio Group Oyj has pursued a consistent dividend policy. The dividend yield for the year 2026 is estimated to be around 2.1%. This indicates that the company aims to provide it...

New support ticket

Explore

Revenio Group Oyj Stock Value

Revenio Group Oyj Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Revenio Group Oyj do?

Revenio Group Oyj Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Revenio Group Oyj Stock Value

Revenio Group Oyj Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Revenio Group Oyj do?

Revenio Group Oyj Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.